A self-limiting, TREM2-dependent anabolic program confers microglial resilience in Alzheimer's disease
- 1Department of Neuroscience, The Ohio State University Wexner Medical Center
Abstract
Microglia are key drivers of Alzheimer's disease (AD), and TREM2, one of the strongest genetic risk factors, enables the disease-associated microglia (DAM) state required for plaque engagement. How TREM2 sustains this protection, and why it falters as disease advances, remain unclear. Using proteomics, single-cell transcriptomics, and in vivo metabolic labeling, we show that plaque-associated microglia mount a TREM2-dependent anabolic program coupling nascent protein synthesis to mitochondrial biogenesis. This program, not the DAM signature, marks phagocytically competent microglia; its loss is associated with proteostatic overload and mitochondrial dysfunction. Unexpectedly, this anabolic program is self-limiting, peaking at low amyloid burden and declining as burden rises. This decline is conserved in humans: across 523 donors, anabolic capacity tracks TREM2 but falls at advanced Braak stage even as DAM signature keeps rising. Thus, anabolic capacity, rather than activation state, marks microglial resilience in AD, and sustained stimulation of phagocytosis by anti-amyloid antibodies risks biosynthetic exhaustion and self-limiting efficacy.
Related
- Reduced SH3RF3 May Protect Against Alzheimer's Disease by Lowering Microglial Pro‐Inflammatory Responses via Modulation of JNK and NFkB Signaling
- Early microglial response to amyloid plaques drives sleep loss in Alzheimer's disease
- Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience
- Astrocytic sEH-EET signaling regulates microglial lysosomal function and suppresses the STING-Type I interferon pathway in Alzheimer's disease
- Female-Biased IL-17/STAT3 Signaling Marks Dementia-Associated Microglial Inflammation in Alzheimer's Disease
BibTeX
@misc{lin2026selflimiting,
title = {{A self-limiting, TREM2-dependent anabolic program confers microglial resilience in Alzheimer's disease}},
author = {D. Lin and J. R. Atkinson and W. Wu and M. Chen and S. Jayasekara and B. M. Segal and A. Ma and J. Gao},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.16.752098},
url = {https://www.biorxiv.org/content/10.64898/2026.09.16.752098v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - A self-limiting, TREM2-dependent anabolic program confers microglial resilience in Alzheimer's disease
AU - D. Lin
AU - J. R. Atkinson
AU - W. Wu
AU - M. Chen
AU - S. Jayasekara
AU - B. M. Segal
AU - A. Ma
AU - J. Gao
PY - 2026
DA - 2026/09/16
PB - bioRxiv
DO - 10.64898/2026.09.16.752098
UR - https://www.biorxiv.org/content/10.64898/2026.09.16.752098v1
AB - Microglia are key drivers of Alzheimer's disease (AD), and TREM2, one of the strongest genetic risk factors, enables the disease-associated microglia (DAM) state required for plaque engagement. How TREM2 sustains this protection, and why it falters as disease advances, remain unclear. Using proteomics, single-cell transcriptomics, and in vivo metabolic labeling, we show that plaque-associated microglia mount a TREM2-dependent anabolic program coupling nascent protein synthesis to mitochondrial biogenesis. This program, not the DAM signature, marks phagocytically competent microglia; its loss is associated with proteostatic overload and mitochondrial dysfunction. Unexpectedly, this anabolic program is self-limiting, peaking at low amyloid burden and declining as burden rises. This decline is conserved in humans: across 523 donors, anabolic capacity tracks TREM2 but falls at advanced Braak stage even as DAM signature keeps rising. Thus, anabolic capacity, rather than activation state, marks microglial resilience in AD, and sustained stimulation of phagocytosis by anti-amyloid antibodies risks biosynthetic exhaustion and self-limiting efficacy.
ER -